Why did DLCL.BO stock drop so sharply intraday?

The intraday fall to **INR 15.98** (-23.54%) was driven by thin liquidity, heavier-than-average volume **60,000**, and stop-loss selling in a small-cap BSE listing. No single public news item explained the drop at time of writing; trading dynamics and receivables concerns likely amplified the move.

What are the key valuation metrics for DLCL.BO stock?

Key metrics show **EPS INR 1.06**, **PE 15.08**, and **PB 0.70** on BSE, with market cap **INR 69,242,427.00**. These numbers suggest bargain valuation against book but note operational ratios such as days sales outstanding **430.96** that raise execution risk.

What short-term price targets exist for DLCL.BO stock?

Meyka AI's model sets a monthly target **INR 21.24** (implied +32.92%) and a quarterly pivot **INR 18.57** (implied +16.20%). These are model projections, not guarantees, and assume improved liquidity or positive news flow to reverse intraday selling pressure.

Should traders buy DLCL.BO stock after the intraday drop?

Traders may consider short-term trades if they use tight stops near **INR 15.39** and limit size because average volume is thin. Investors should wait for evidence of improved cash conversion and lower receivables before adding to long-term holdings in this healthcare small cap.

IN Stocks

DLCL.BO Dr. Lalchandani Labs BSE -23.54% intraday 28 Jan 2026: watch INR 15.39

ByDanny Kontos January 28, 2026January 28, 2026

We saw DLCL.BO stock plunge -23.54% intraday on 28 Jan 2026, closing at INR 15.98 on the BSE as selling accelerated after the open at INR 15.39. Volume rose to 60,000 shares versus an average 25,333, which shows above-normal interest while price tested the day low. We focus on valuation, technical support, Meyka AI grading and near-term forecasts to explain why this healthcare small cap appears among today’s top losers.